FDA Approves ULTOMIRIS — Alexion Pharmaceuticals Inc.

# FDA Approves Alexion Pharmaceuticals' ULTOMIRIS for Complement-Mediated Disorders Alexion Pharmaceuticals Inc. received FDA approval for ULTOMIRIS (ravulizumab), an intravenous complement inhibitor, positioning the company to compete in the rare disease market and potentially expand its market share beyond its existing complement-targeting therapies. The approval of this long-acting C5 inhibitor is expected to drive significant revenue growth for Alexion in treating paroxysmal nocturnal hemoglobinuria and other rare blood disorders.